Benzinga•2026-04-17
Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss RaceSANA — Sana Biotechnology Inc
NASDAQ · Biotechnology · Biotechnology
$3.70-25.10%Market cap827.29M
- Latest Close
- $3.7
- 30-Day Move
- -25.1%
- Market Cap
- $827M
- Shares Outstanding
- 266,870,000
- P/B Ratio
- 6.74
- ROE
- -151.8%
NASDAQ:SANABiotechnology / BiotechnologyDelayed public snapshot
Sana Biotechnology Inc
A read-only Alphactor snapshot forSana Biotechnology Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$3.7
30-Day Move
-25.1%
Market Cap
$827M
Shares Outstanding
266,870,000
P/B Ratio
6.74
ROE
-151.8%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$3.70
-25.1%last 90 delayed daily bars
Market cap$827M
90D High
$5.36
90D Low
$2.66
Avg Volume
3,106,525
What stands out
SANA is down 25.1% over the last 30 trading days shown on this page.
Latest operating income is $-61M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Dark Pool Short %
72.0%
Fundamentals snapshot
Latest Close
$3.7
30-Day Move
-25.1%
Market Cap
$827M
Shares Outstanding
266,870,000
P/B Ratio
6.74
ROE
-151.8%
ROA
-58.6%
Debt / Equity
0
Current Ratio
1.89
Latest Revenue
$0
Financial statement snapshot
Revenue
$0
Gross Profit
--
Operating Income
$-61M
Net Income
$-59M
Gross Margin
--
Net Margin
--
Current Ratio
1.89
Debt / Equity
0.00
Quality snapshot
Altman Z
-5.70
Distress
Piotroski
1
Weak (0-3)
Cash Conversion
0.59x
Rule of 40
--
Insufficient data
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-273M | $-269M | $-311M |
| 2023-12-31 | $0 | $-286M | $-283M | $-274M |
| 2024-12-31 | $0 | $-271M | $-267M | $-257M |
| 2025-12-31 | $0 | $-206M | $-244M | $-145M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 10,508,590 | 0.04% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 5,439,344 | 0.02% | 2025-12-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 4,563,402 | 0.02% | 2026-02-28 |
| iShares Trust-iShares Russell 2000 ETF | 3,982,307 | 0.01% | 2026-02-28 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 3,146,614 | 0.01% | 2026-02-28 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 2,857,700 | 0.01% | 2026-02-28 |
| VANGUARD WORLD FUND-Vanguard U.S. Growth Fund | 1,902,196 | 0.01% | 2025-11-30 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1,765,081 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Qube Research & Technologies
Filed 2025-05-15
--
--
Two Sigma Advisers
Filed 2025-11-14
--
--
FMR LLC (Fidelity)
Filed 2026-02-17
$152M
-0.0%
BlackRock
Filed 2024-05-10
$90M
--
Vanguard Group
Filed 2026-01-29
$43M
+14.5%
Citadel Advisors
Filed 2025-11-14
$23M
--
Geode Capital Management
Filed 2026-02-09
$17M
+20.3%
Dark-pool activity snapshot
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.